To develop and improve offerings in the area of predictive toxicology
Contract research specialist Cyprotex has signed a research agreement with Pfizer.
The Macclesfield, Cheshire, UK-based firm’s US subsidiary Apredica, which it acquired in 2010, will take part in an 18-month collaborative research project with the pharmaceutical giant.
No financial details were revealed about the agreement, which is split into two stages with the second stage being dependent on the achievement of certain milestones.
Cyprotex says the collaboration is a research-based project which aim to ‘evaluate, further develop, and improve several of Cyprotex’s proprietary offerings in the area of predictive toxicology’.
Chief executive Dr Anthony Baxter said: ‘We are delighted to be able to continue our relationship with Pfizer. This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction.
‘Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients.’
Cyprotex specialises in preclinical ADME Tox, both in vitro (laboratory experiments) and in silico (computer modelling).